Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression

Journal of General Virology

Volumn 96, Issue 8, 2015, Pages 2360-2371

  Di Pilato, Mauro ^a   Sánchez Sampedro, Lucas ^a   Mejías Pérez, Ernesto ^a   Sorzano, Carlos Oscar S ^a   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; GENE EXPRESSION; HELA CELL LINE; HUMAN; HUMAN CELL; IMMUNIZATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROMOTER SPACER LENGTH; SPLEEN CELL; VACCINIA VIRUS; ANIMAL; BAGG ALBINO MOUSE; GENE VECTOR; GENETICS; IMMUNOLOGY; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MALE; PARASITOLOGY;

POXVIRIDAE; VACCINIA VIRUS;

LACK ANTIGEN, LEISHMANIA; PARASITE ANTIGEN; PROTOZOAL PROTEIN;

ANIMALS; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION; GENETIC VECTORS; HUMANS; IMMUNIZATION; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MALE; MICE, INBRED BALB C; PROMOTER REGIONS, GENETIC; PROTOZOAN PROTEINS; VACCINIA VIRUS;

EID: 84940186615     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.000183     Document Type: Article

References (56)

1. Ahn, B. Y., Gershon, P. D. & Moss, B. (1994). RNA polymerase- associated protein Rap94 confers promoter specificity for initiating transcription of vaccinia virus early stage genes. J Biol Chem 269, 7552-7557
2. Assarsson, E., Greenbaum, J. A., Sundstrom, M., Schaffer, L., Hammond, J. A., Pasquetto, V., Oseroff, C., Hendrickson, R. C., Lefkowitz, E. J. & other authors (2008). Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A 105, 2140-2145.
3. Baur, K., Brinkmann, K., Schweneker, M., Patzold, J., Meisinger- Henschel, C., Hermann, J., Steigerwald, R., Chaplin, P., Suter, M. & Hausmann, J. (2010). Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immuno- dominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses. J Virol 84, 8743-8752.
4. Belnoue, E., Costa, F. T., Frankenberg, T., Vigário, A. M., Voza, T., Leroy, N., Rodrigues, M. M., Landau, I., Snounou, G. & Rénia, L. (2004). Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 172, 2487-2495
5. Brandler, S., Lepelley, A., Desdouits, M., Guivel-Benhassine, F., Ceccaldi, P. E., Lévy, Y., Schwartz, O. & Moris, A. (2010). Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect. J Virol 84, 5314-5328.
6. Bronte, V., Carroll, M. W., Goletz, T. J., Wang, M., Overwijk, W. W., Marincola, F., Rosenberg, S. A., Moss, B. & Restifo, N. P. (1997). Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A 94, 3183-3188.
7. Broyles, S. S., Yuen, L., Shuman, S. & Moss, B. (1988). Purification of a factor required for transcription of vaccinia virus early genes. J Biol Chem 263, 10754-10760.
8. Chakrabarti, S., Sisler, J. R. & Moss, B. (1997). Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23, 1094-1097.
9. Cochran, M. A., Puckett, C. & Moss, B. (1985). In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals. J Virol 54, 30-37.
10. Crowe, S. R., Turner, S. J., Miller, S. C., Roberts, A. D., Rappolo, R. A., Doherty, P. C., Ely, K. H. & Woodland, D. L. (2003). Differential antigen presentation regulates the changing patterns of CD8+T cell immunodominance in primary and secondary influenza virus infections. J Exp Med 198, 399-410.
11. Darrah, P. A., Patel, D. T., De Luca, P. M., Lindsay, R. W., Davey, D. F., Flynn, B. J., Hoff, S. T., Andersen, P., Reed, S. G. & other authors (2007). Multifunctional TH1 cells define a correlate of vaccine- mediated protection against Leishmania major. Nat Med 13, 843-850
12. Darrah, P. A., Hegde, S. T., Patel, D. T., Lindsay, R. W., Chen, L., Roederer, M. & Seder, R. A. (2010). IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med 207, 1421-1433.
13. Di Pilato, M., Mejías-Pérez, E., Gómez, C. E., Perdiguero, B., Sorzano, C. O. & Esteban, M. (2013). New vaccinia virus promoter as a potential candidate for future vaccines. J Gen Virol 94, 2771-2776.
14. García-Arriaza, J. & Esteban, M. (2014). Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother 10, 2235-2244
15. Gómez, C. E., Nájera, J. L., Jiménez, E. P., Jiménez, V., Wagner, R., Graf, M., Frachette, M. J., Liljestrom, P., Pantaleo, G. & Esteban, M. (2007a). Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV- 1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25, 2863-2885.
16. Gómez, C. E., Nájera, J. L., Jiménez, V., Bieler, K., Wild, J., Kostic, L., Heidari, S., Chen, M., Frachette, M. J. & other authors (2007b). Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25, 1969-1992.
17. Gómez, C. E., Nájera, J. L., Krupa, M., Perdiguero, B. & Esteban, M. (2011). MVA and YVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther 11, 189-217.
18. Gómez, C. E., Perdiguero, B., Garcia-Arriaza, J. & Esteban, M. (2012). Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother 8, 1192-1207.
19. Gómez, C. E., Perdiguero, B., García-Arriaza, J. & Esteban, M. (2013). Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines 12, 1395-1416.
20. Gonzalez-Aseguinolaza, G., Taladriz, S., Marquet, A. & Larraga, V. (1999). Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum. Eur J Biochem 259, 909-916.
21. Gurunathan, S., Stobie, L., Prussin, C., Sacks, D. L., Glaichenhaus, N., Iwasaki, A., Fowell, D. J., Locksley, R. M., Chang, J. T. & other authors (2000). Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+T cells. J Immunol 165, 915-924.
22. Ha, S. J., West, E. E., Araki, K., Smith, K. A. & Ahmed, R. (2008). Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol Rev 223, 317-333.
23. Hagensee, M. E., Carter, J. J., Wipf, G. C. & Galloway, D. A. (1995). Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies. Virology 206, 174-182
24. Hagler, J. & Shuman, S. (1992). Structural analysis of ternary complexes of vaccinia RNA polymerase. Proc Natl Acad Sci U S A 89, 10099-10103.
25. Hansen, S. G., Vieville, C., Whizin, N., Coyne-Johnson, L., Siess, D. C., Drummond, D. D., Legasse, A. W., Axthelm, M. K., Oswald, K. & other authors (2009). Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 15, 293-299.
26. Hansen, S. G., Ford, J. C., Lewis, M. S., Ventura, A. B., Hughes, C. M., Coyne-Johnson, L., Whizin, N., Oswald, K., Shoemaker, R. & other authors (2011). Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527.
27. Isshiki, M., Zhang, X., Sato, H., Ohashi, T., Inoue, M. & Shida, H. (2014). Effects of different promoters on the virulence and immunogenicity of a HIV-1 Env-expressing recombinant vaccinia vaccine. Vaccine 32, 839-845
28. Kastenmuller, W., Gasteiger, G., Gronau, J. H., Baier, R., Ljapoci, R., Busch, D. H. & Drexler, I. (2007). Cross-competition of CD8+T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med 204, 2187-2198
29. Launois, P., Pingel, S., Himmelrich, H., Locksley, R. & Louis, J. (2007). Different epitopes of the LACK protein are recognized by V beta 4 V alpha 8 CD4+T cells in H-2b and H-2d mice susceptible to Leishmania major. Microbes Infect 9, 1260-1266.
30. Macedo, A. B., Sánchez-Arcila, J. C., Schubach, A. O., Mendonça, S. C., Marins-Dos-Santos, A., de Fatima Madeira, M., Gagini, T., Pimentel, M. I. & De Luca, P. M. (2012). Multifunctional CD4+ T cells in patients with American cutaneous leishmaniasis. Clin Exp Immunol 167, 505-513.
31. Mougneau, E., Altare, F., Wakil, A. E., Zheng, S., Coppola, T., Wang, Z. E., Waldmann, R., Locksley, R. M. & Glaichenhaus, N. (1995). Expression cloning of a protective Leishmania antigen. Science 268, 563-566.
32. Moutaftsi, M., Salek-Ardakani, S., Croft, M., Peters, B., Sidney, J., Grey, H. & Sette, A. (2009). Correlates of protection efficacy induced by vaccinia virus-specific CD8+T-cell epitopes in the murine intranasal challenge model. Eur J Immunol 39, 717-722.
33. Nájera, J. L., Gómez, C. E., García-Arriaza, J., Sorzano, C. O. & Esteban, M. (2010). Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One 5, e11406.
34. Perdiguero, B., Gómez, C. E., Di Pilato, M., Sorzano, C. O., Delaloye, J., Roger, T., Calandra, T., Pantaleo, G. & Esteban, M. (2013). Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. PLoS One 8, e74831.
35. Peters, N. C., Pagán, A. J., Lawyer, P. G., Hand, T. W., Henrique Roma, E., Stamper, L. W., Romano, A. & Sacks, D. L. (2014). Chronic parasitic infection maintains high frequencies of short-lived Ly6C+CD4+ effector T cells that are required for protection against re-infection. PLoS Pathog 10, e1004538.
36. Ramírez, J. C., Gherardi, M. M. & Esteban, M. (2000). Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74, 923-933.
37. Ray, A. & Dittel, B. N. (2010). Isolation of mouse peritoneal cavity cells. J Vis Exp 35, 1488.
38. Reece, W. H., Pinder, M., Gothard, P. K., Milligan, P., Bojang, K., Doherty, T., Plebanski, M., Akinwunmi, P., Everaere, S. & other authors (2004). A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 10, 406-410.
39. Reyes-Sandoval, A., Wyllie, D. H., Bauza, K., Milicic, A., Forbes, E. K., Rollier, C. S. & Hill, A. V. (2011). CD8+T effector memory cells protect against liver-stage malaria. J Immunol 187, 1347-1357.
40. Rigato, P. O., de Alencar, B. C., de Vasconcelos, J. R., Dominguez, M. R., Araújo, A. F., Machado, A. V., Gazzinelli, R. T., Bruna-Romero, O. & Rodrigues, M. M. (2011). Heterologous plasmid DNA prime- recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi. Infect Immun 79, 2120-2130.
41. Román, E., Miller, E., Harmsen, A., Wiley, J., Von Andrian, U. H., Huston, G. & Swain, S. L. (2002). CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. J Exp Med 196, 957-968.
42. Sánchez-Sampedro, L., Gómez, C. E., Mejías-Pérez, E., Sorzano, C. O. & Esteban, M. (2012). High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection. PLoS One 7, e38859.
43. Sato, H., Jing, C., Isshiki, M., Matsuo, K., Kidokoro, M., Takamura, S., Zhang, X., Ohashi, T. & Shida, H. (2013). Immunogenicity and safety of the vaccinia virus LC16m8D vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime- recombinant vaccinia virus boost protocol. Vaccine 31, 3549-3557
44. Schmidt, N. W., Podyminogin, R. L., Butler, N. S., Badovinac, V. P., Tucker, B. J., Bahjat, K. S., Lauer, P., Reyes-Sandoval, A., Hutchings, C. L. & other authors (2008). Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc Natl Acad Sci U S A 105, 14017-14022.
45. Sette, A., Grey, H., Oseroff, C., Peters, B., Moutaftsi, M., Crotty, S., Assarsson, E., Greenbaum, J., Kim, Y. & other authors (2009). Definition of epitopes and antigens recognized by vaccinia specific immune responses: their conservation in variola virus sequences, and use as a model system to study complex pathogens. Vaccine 27 (Suppl 6), G21-G26.
46. Terahara, K., Ishii, H., Nomura, T., Takahashi, N., Takeda, A., Shiino, T., Tsunetsugu-Yokota, Y. & Matano, T. (2014). Vaccine-induced CD107a+ CD4+T cells are resistant to depletion following AIDS virus infection. J Virol 88, 14232-14240.
47. Uzonna, J. E., Spath, G. F., Beverley, S. M. & Scott, P. (2004). Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J Immunol 172, 3793-3797.
48. Wennier, S. T., Brinkmann, K., Steinhaußer, C., Maylander, N., Mnich, C., Wielert, U., Dirmeier, U., Hausmann, J., Chaplin, P. & Steigerwald, R. (2013). A novel naturally occurring tandem promoter in modified vaccinia virus Ankara drives very early gene expression and potent immune responses. PLoS One 8, e73511.
49. Wilson, E. H. & Hunter, C. A. (2008). Immunodominance and recognition of intracellular pathogens. J Infect Dis 198, 1579-1581.
50. Wyatt, L. S., Earl, P. L., Vogt, J., Eller, L. A., Chandran, D., Liu, J., Robinson, H. L. & Moss, B. (2008). Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines. Vaccine 26, 486-493.
51. Yang, Z., Bruno, D. P., Martens, C. A., Porcella, S. F. & Moss, B. (2010). Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A 107, 11513-11518.
52. Yang, Z., Bruno, D. P., Martens, C. A., Porcella, S. F. & Moss, B. (2011a). Genome-wide analysis of the 59 and 39 ends of vaccinia virus early mRNAs delineates regulatory sequences of annotated and anomalous transcripts. J Virol 85, 5897-5909
53. Yang, Z., Reynolds, S. E., Martens, C. A., Bruno, D. P., Porcella, S. F. & Moss, B. (2011b). Expression profiling of the intermediate and late stages of poxvirus replication. J Virol 85, 9899-9908.
54. Yang, Z., Maruri-Avidal, L., Sisler, J., Stuart, C. A. & Moss, B. (2013). Cascade regulation of vaccinia virus gene expression is modulated by multistage promoters. Virology 447, 213-220.
55. Yewdell, J. W. & Bennink, J. R. (1999). Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17, 51-88.
56. Younes, S. A., Yassine-Diab, B., Dumont, A. R., Boulassel, M. R., Grossman, Z., Routy, J. P. & Sekaly, R. P. (2003). HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+T cells endowed with proliferative capacity. J Exp Med 198, 1909-1922